Bionoid Pharma, Inc.
BINP · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.01 | 0.58 | -0.01 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -58.64 | 0.00 | 0.00 | -1,429.21 |
| Quality | ||||
| ROIC | -5.32% | 0.00% | 0.00% | -3.61% |
| Gross Margin | 0.00% | 0.00% | 558.96% | -1,487.51% |
| Cash Conversion Ratio | -0.17 | 1.34 | 0.15 | -1.71 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -14.88% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.44 | 0.00 | 0.00 | -15.15 |
| Interest Coverage | -513.37 | -605.91 | 28.73 | -90.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -2.66 |